India Pharma Outlook Team | Tuesday, 31 March 2026
Lupin Ltd has received tentative approval from the United States Food and Drug Administration for its generic version of Sugammadex injection, which is used to reverse the effects of certain muscle relaxants used during surgery.
The approval has been received for Lupin's abbreviated new drug application for Sugammadex Injection in two different strengths: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in single-dose vials. The drug has already been found to be bioequivalent to Bridion, which is a drug developed by Merck.
The drug is used to reverse neuromuscular blockade in patients who have undergone surgery, which is generally caused by rocuronium bromide and vecuronium bromide, which are administered during surgery to relax muscles. The drug can be administered in both adults and children aged two years and above.
The fact that Lupin Ltd has received tentative approval from the USFDA indicates that its drug has passed all quality, safety, and efficacy tests, but its commercialization will depend on the patents and exclusivities available for the reference drug.
Also Read: Teva's Biosimilars Expansion Advances With Key FDA Approval
This will further add to Lupin Ltd's portfolio in the US market, especially in the injectables segment, which is a key segment of the drug market and has witnessed steady demand.
Once Lupin Ltd receives final approval, it will enable the company to enter this highly regulated and competitive market with its drug, which will help expand its presence in this market segment.
.jpg)
.jpg)
